The efficacy of an antiretroviral (ARV) treatment regimen depends on the activity of the
regimen's individual ARV drugs and the number of HIV-1 mutations required for the …

Lopinavir is a novel protease inhibitor (PI) developed from ritonavir. Coadministration with
low-dose ritonavir significantly improves the pharmacokinetic properties and hence the …

Background The use of either efavirenz or lopinavir–ritonavir plus two nucleoside reverse-
transcriptase inhibitors (NRTIs) is recommended for initial therapy for patients with human …

Dyslipidemia is a common problem affecting HIV-infected patients receiving antiretroviral
therapy. Since publication of preliminary guidelines in 2000 [1], numerous studies have …

Background Lopinavir is a newly developed inhibitor of human immunodeficiency virus
(HIV) protease that, when formulated with ritonavir, yields mean trough plasma lopinavir …

Lopinavir/ritonavir is the first and only coformulated HIV-1 protease inhibitor (PI). Large
clinical trials have demonstrated lopinavir/ritonavir's clinical efficacy in both antiretroviral …

Objective: To evaluate the antiviral activity, safety, pharmacokinetics, and pharmacokinetics/
pharmacodynamics of dolutegravir (DTG), a next-generation HIV integrase inhibitor (INI), as …

Boosted protease inhibitor regimens combine ritonavir with a second,'boosted'protease
inhibitor to enhance patient exposure to the latter agent, thereby preventing or overcoming …

ObjectiveNew information warrants updated recommendations for the 4 central issues in
antiretroviral therapy: when to start, what drugs to start with, when to change, and what to …

The availability of an increasing number of antiretroviral agents and the rapid evolution of
new information have introduced substantial complexity into treatment regimens for persons …